52 results about "Glycolipid" patented technology

This invention relates to the field of semiconductor cleaning technology and discloses a cleaning agent for semiconductor silicon wafers and its preparation method. This cleaning agent aims to solve the problem that traditional strong alkaline or phosphate-based wet electronic chemical cleaning agents easily corrode the silicon wafer surface, damage the crystal lattice, and thus affect electrical performance. This cleaning agent utilizes a multi-component synergistic effect: a surfactant system composed of alkyl glycosides and sophorolipids enhances particle wetting and stripping; lipase and silicon-pharmacoprotein precisely catalyze the removal of specific contaminants; sodium gluconate complexes metal ions; gelatin-polyacrylamide copolymer disperses contaminants to prevent secondary contamination; glycerol and trehalose maintain enzyme activity; and ultrapure water ensures the system meets the electronic-grade purity standards for wet electronic chemicals. Overall, it avoids strong alkaline corrosion, maintains the integrity of the silicon wafer lattice, and improves particle removal efficiency, meeting the high standards required for wet electronic chemical-based silicon wafer cleaning agents in advanced processes.

The application discloses a use of a pharmaceutical composition of a phenolic acid compound and probiotics, and particularly relates to a combination of chlorogenic acid and lactobacillus reuteri. The combination of chlorogenic acid and lactobacillus reuteri can improve glycolipid metabolic disorder, improve cognitive dysfunction, emotional disorder and delay aging, and can be used for preparing a medicine for treating metabolic disorder combined with neuropsychiatric diseases.

The present invention relates to mutants of the bumblebee Yarrowia SBLE enzyme having modulated transesterification and / or esterification activity compared to the bumblebee Yarrowia SBLE enzyme, and to homologues of the bumblebee Yarrowia SBLE enzyme, such as the C. bogoriensis LE enzyme, the B. batistae LE enzyme and the R. riograndensis LE enzyme, having transesterification and esterification activity on bolaform glycolipids. The present invention also provides genetically modified yeast strains comprising a mutant LE enzyme or a bumblebee Yarrowia SBLE enzyme homologue of the present invention. The present invention further provides the use and methods of the mutant LE enzymes, the bumblebee Yarrowia SBLE enzyme homologues and the modified yeast strains of the present invention for the production of acidic glycolipids, lactone-form glycolipids and / or glycolipid oligomers / polymers / esters. The present invention also provides the three-dimensional structure of the bumblebee Yarrowia SBLE enzyme and its use for the design of mutants having modulated hydrolysis and / or transesterification activity.

The present invention relates to a method for producing glycolipids in recombinant host cells and to a novel glycolipid obtained by said method as well as nucleic acid molecules used in this method.

This invention discloses a functional Cistanche deserticola polysaccharide, its preparation method, and its applications. Using Cistanche deserticola as raw material, the polysaccharide is first extracted by cell wall disruption using an oxygen free radical-cellulase synergistic technology. The optimal extraction parameters are optimized through single-factor experimental design, overcoming the limitations of traditional methods and achieving efficient, green, and activity-preserving extraction of Cistanche deserticola polysaccharide, providing a high-quality material basis for subsequent research. The Cistanche deserticola polysaccharide extracted by this method can slow down weight gain in obese C57BL / 6J mice induced by a high-fat diet and improve glucose and lipid metabolism disorders. It also induces the production of important biomarkers such as indole, decanoic acid, and nonanoic acid by the intestinal flora of mice. This invention obtains Cistanche deserticola polysaccharides with specific biological activities, achieving high-quality utilization of Cistanche deserticola.

The application provides a water-triggered self-assembly gel, a use method and application thereof. The water-triggered self-assembly gel comprises 5-aminolevulinic acid hydrochloride 5-15 wt%, phospholipid 5-10 wt%, anionic glycolipid surfactant 0.2-0.8 wt%, polyethylene glycol 50-60 wt%, propylene glycol 20-27 wt% and antioxidant 0.05-0.1 wt%, and water <0.1 wt%; the mass ratio of the polyethylene glycol and the propylene glycol is (2-2.5):1. The water content of the water-triggered self-assembly gel is extremely low, so that the stability is good and the storage is easy; when used, the water-triggered mechanism of transdermal water loss can be used to actively extract water from the stratum corneum, the phase transition of the phospholipid from the disordered lamellar phase to the liposome is quickly completed, the nanometer liposome with uniform particle size and high encapsulation efficiency is spontaneously formed, the 5-ALA hydrochloride is wrapped, and the 5-ALA hydrochloride can be efficiently delivered to the deep layer of the skin.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

The application discloses a kind of blood vessel microfluidic device and method suitable for glycolipid drug test, the device constructs three-dimensional biomimetic microvessel chip using induced pluripotent stem cells, and integrates multiple sensors;Through integrated environmental control module, programmed blood flow loading and drug exposure are realized.Intelligent analysis system includes multimodal intelligent observation module, based on microscope imaging and artificial intelligence speed measurement technology, three-dimensional flow field is inverted;Microcirculation digital twin module reconstructs blood vessels based on medical imaging and constructs calibratable hemodynamic model, for simulation and prediction;And wet-dry interaction module, through two-way interface, realizes "experiment-simulation" closed loop, injects entity data into digital twin to calibrate, and converts the prediction instruction of digital twin into chip control command to drive verification experiment.The system realizes complete technical chain from biomimetic model construction, intelligent observation, digital twin simulation to active experiment optimization.

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

The present invention relates to a process of separating an acidic sophorolipid, or a lactonic sophorolipid, especially an acidic sophorolipid enriched with acetylated acidic sophorolipid from a lactonic / acidic sophorolipid-containing product and the acidic sophorolipid, especially the acid-ic sophorolipid enriched with acetylated acidic sophorolipid obtained by said process.

The application discloses a glycolipid metabolism index prediction model for predicting cardiovascular events and a construction method thereof. The model aims to solve the problems that existing cardiovascular risk assessment tools are not accurate in describing glycolipid metabolism state and are single in prediction dimension. The construction method comprises the following steps: obtaining demographic information and clinical data of a subject; measuring the content of high-density lipoprotein subcomponent HDL2b; taking body mass index, lipoprotein a, triglyceride-glucose index and HDL2b as core evaluation parameters, taking whether a cardiovascular event occurs within five years as a target variable, and adopting a multivariate logistic regression to construct a prediction model. The model can realize rapid and accurate stratification of the risk of cardiovascular event occurrence of an individual by quantifying index scores and adding up. The application integrates multi-dimensional key indicators of glycolipid metabolism, has the advantages of high prediction performance, clear risk stratification and strong repeatability, and is suitable for early risk screening and evaluation of cardiovascular diseases.

This invention belongs to the field of biomedical inorganic nanomaterials technology, and discloses a copper-doped bioglass and its application in the treatment of chronic liver injury and hepatic osteodystrophy. The bioglass is prepared by a sol-gel method, with copper as a dopant (Cu). 2+ It is doped in a form with a doping amount of 0.1-5 wt%, has a mesoporous structure, a particle size of approximately 163 nm, and can slowly release Cu in environments with pH 7.4 or 5.5. 2+ The treatment duration is 48-96 hours. This invention is the first to use the aforementioned material for the simultaneous treatment of chronic liver injury (such as metabolic-associated steatohepatitis) and its secondary hepatic osteopathy, achieving liver-targeted therapy via intravenous injection. Its mechanism of action includes: regulating glucose and lipid metabolism in the liver, enhancing mitochondrial function, and inhibiting inflammation and fibrosis; simultaneously upregulating the liver-derived factor LCAT, promoting osteogenic differentiation via the liver-bone axis, thereby synergistically improving liver injury and bone loss. This invention overcomes the limitations of separate liver and bone treatment, providing a safe and effective integrated treatment strategy.

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

This invention belongs to the field of exosome preservation technology and discloses a stabilizer composition for exosome cryopreservation and its application. The stabilizer composition for exosome cryopreservation provided by this invention consists of the following components and their amounts: phytosphingosine: 0.1%-0.2%; cerebroside sulfate: 0.05%-0.1%; trehalose: 2%-5%; lipid-soluble antioxidant: 0.01%-0.05%; HEPES buffer: 10-20 mM; metal ion chelating agent: 0.01%-0.05%. The composition of this invention forms a "gradient protection" through the membrane insertion of phytosphingosine and the shallow negative charge shielding of cerebroside sulfate, enabling stable cryopreservation of exosomes for more than one week with a bioactivity retention of >85%. This preservative is animal-free, easy to use, and effective, making it suitable for the clinical translation and practical application of exosomes.

The present application relates to the technical field of biological medicine, and discloses a composition containing probiotics and application thereof. Specifically, the lactobacillus gasseri with the preservation number of CGMCC No.15501 provided by the present application can drive the polarization transformation of macrophages, improve the glycolipid metabolism and inflammatory reaction caused by liver cancer, and thus has great application value in delaying the development of liver cancer and inhibiting the proliferation of liver cancer cells.

Materials and methods are provided for producing bio-derivatized sophorolipids (SLP) via yeast fermentation, wherein SLP molecules are transformed in situ into derivative molecules through selective modification of nutrients and feedstock. The final percentage of linear-type SLP with respect to total SLP produced is at least 70% or greater, through a single fermentation process, thereby eliminating the need for additional downstream processing or chemical reactions.

The invention relates to extremely mild, concentrated cleansing compositions to create personal care formulations. The mildness of composition towards the skin is due to the synergy of constituent members. More specifically, the compositions comprise of cocamidopropyl PG dimonium chloride phosphate, an alkyl polyglucoside, and sophorolipids to give the superlative performance in terms of foam and lather with extreme gentleness towards the stratum corneum, the uppermost layer of the skin. The concentrated, self-preserving, ultra-mild compositions of the present invention are particularly suitable for cleansing of sensitive skin (babies and sensitive body parts), irritated skin (medically compromised) and very dry skin (senior citizens). Also process for preparing such ultra-mild cleansing composition is provided.

This invention discloses the application of adenosine deaminase or its modified forms in the preparation of therapeutic drugs that improve pancreatic islet inflammation and protect pancreatic β-cell function in diabetic patients. This invention is the first to discover that exogenous ADA, through a systemic clearance-local decompression mechanism, enhances circulating ADO clearance, reduces tissue ADO load, restores compensatoryly elevated tissue ADA activity to normal, significantly reduces macrophage infiltration in the islets, inhibits inflammatory factor expression, promotes β-cell proliferation and functional recovery, and improves glucose and lipid metabolism. This invention provides a disease-modifying therapy for diabetes that can simultaneously regulate immunity and metabolism, possessing extremely high clinical application value.

The present disclosure provides methods of stabilizing foam in sweetened beverages wherein the beverages comprise a glycolipid enriched beverage base. Also disclosed are glycolipid enriched beverage bases and beverages containing the enriched beverage base.

This disclosure relates to compositions comprising glycolipid nanoparticles and a therapeutic comprising: a) ionizable lipid, b) poly(ethylene glycol) lipid, c) sterol, and d) glycolipid. In certain embodiments, the average diameter of the particles is about between 30 and 180 nm. In certain embodiments, the therapeutic is a nucleic acid encoding a therapeutic protein.

The application relates to the technical field of cosmetics, in particular to a double-dosage full-transparent shake milk and a preparation method thereof, the shake milk comprises an A phase and a B phase, the A phase comprises the following components: 3-10% of component No. 1, 3-10% of component No. 2, 1-5% of component No. 3, 1-5% of component No. 4, 2-10% of component No. 5, 0.01-1% of component No. 6, 0.05-0.15% of an emulsifier, 0.01-1% of an antioxidant; the emulsifier is a glycolipid, the component No. 1 is a coco-caprylate / caprate, and the component No. 2 is C9-12 alkane; the B phase comprises the following components: 0.01-0.5% of disodium EDTA, 0.001-0.2% of galactoarabinan, 0.01-0.15% of hydrolyzed sodium hyaluronate, 0.1-0.8% of a preservative, and the rest is water; the density difference between the A phase and the B phase is greater than or equal to 0.14593; the shake milk has the advantages that after the shake milk is shaken and then is left to stand, the water phase, the oil phase and the water-oil interface can reach a full-transparent state.

To provide transparent cosmetic compositions that exhibit a stable form even under high temperature conditions.SOLUTION: The present invention relates to a cosmetic composition containing a sophorolipid, a di-rhamnolipid and an ionic salt, a transparent cosmetic composition being able to be provided by containing the glycolipid. Also, by applying an ionic salt to the composition to reduce the ionic repulsion between the glycolipid molecules, a transparent cosmetic composition with improved stability being able to be provided through an improved micelle packing structure.SELECTED DRAWING: Figure 1

A cleansing skin brightening cleansing composition includes a blend of hydroxy acids including at least one alpha-hydroxy acid, at least one beta-hydroxy acid, and at least one poly-hydroxy acid niacinamide (vitamin B3), at least one a bio-based glycolipid surfactant, at least one thickener, at least one clay, and a cosmetically acceptable solvent that includes at least water. The composition has a pH in a range from about 4.4 to about 5.0. The composition can be used as a daily skin cleanser, or a facial mask or a spot treatment product, and / or the combinations thereof, and when applied to skin confers gentle exfoliation, skin brightening and whitening, and evens skin tone.

This invention discloses an essential oil for improving glucose and lipid metabolism, its preparation method, and its application, belonging to the field of plant essential oil pharmaceutical technology. This invention reveals for the first time the significant effect of a compound formula composed of lemon myrtle essential oil as the principal ingredient, supplemented with other synergistic plant essential oils, on improving glucose and lipid metabolism (especially obesity and non-alcoholic fatty liver disease). The essential oil contains ≥80% total citral (geranialdehyde + neraldehyde), prepared through pretreatment (pulverization), soaking, distillation, and drying steps; the process is simple and easy to produce. This invention is adaptable to various dosage forms such as oral soft capsules and topical roll-on products, and innovatively develops a nanoemulsion form, increasing its oral bioavailability by 2 times. The product protection scope of this invention is clear, the process is stable, and the application scenarios are well-defined, providing a new option for developing safe and effective natural-derived drugs or health products for treating glucose and lipid metabolism disorders, and has significant application value.

A cleaning agent composition for cleaning hard surfaces includes a sophorolipid and an antimicrobial agent that comprises a quaternary ammonium compound. The sophorolipid and the quaternary ammonium compound show unexpected synergy.

A genetically modified human beta-glucocerebrosidase (GCase) is disclosed. The genetically modified GCase comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 2; and comprising mutations at coordinates L34P, K224N / G, T369E and N370D, where the coordinates correspond to said SEQ ID NO: 2; and capable of catalyzing hydrolysis of a glycolipid glucosylceramide (GlcCer). Pharmaceutical compositions comprising the genetically modified GCase and therapeutic methods of using same are also disclosed.

This application discloses an emulsion composition, an emulsion, its preparation method, uses, and cosmetics, belonging to the field of chemical production technology. The technical solution is as follows: an emulsion composition containing at least two of Bacillus ferment, glycolipid emulsifiers, and phospholipid emulsifiers, and containing at least Bacillus ferment. This emulsion composition uses Bacillus ferment as the main emulsifier, combined with other biological emulsifiers, to enhance the application range and stability of the D-phase emulsion system. Furthermore, this application has also found through testing that when the D-phase emulsion system is used in conjunction with a special oil phase, the brightening and soothing abilities of the emulsion can be further enhanced.